Pirche Ag

Nov 29, 2024 | academic.oup.com | Von Gabriele Hoerschelmann |Del Moral |Covadonga Bachiller Lopez |Covadonga Carrasco López |Pirche Ag

Donor-derived cell-free DNA (dd-cfDNA) shows good diagnostic performance for the detection of antibody-mediated rejection (AMR) in kidney transplant recipients (KTR). However, the clinical benefits of dd-cfDNA monitoring need to be established. Early diagnosis of AMR at potentially reversible stages may be increasingly important due to emerging treatment options for AMR.

Feb 28, 2024 | karger.com | Pirche Ag

Introduction: Eurotransplant established the acceptable mismatch (AM) program to facilitate timely kidney transplantations of highly sensitized patients, but long-term granular clinical and immunological outcomes regarding overall graft survival and de novo DSA (dnDSA) formation are still intensively researched.